Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
Khokon Miah Akanda/LinkedIn
May 30, 2026, 18:12

Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug

Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:

“FDA approves a first-in-class hypertension drug!

The US FDA has recently approved Baxfendy (baxdrostat) by AstraZeneca, the first-ever aldosterone synthase inhibitor for hypertension treatment.

What makes this approval significant is its completely new mechanism of action. Instead of only managing symptoms, the drug directly targets aldosterone production, a hormone linked to persistently high blood pressure and cardiovascular risk.

In Phase III trials, the drug demonstrated clinically meaningful reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications.

This marks one of the most important cardiovascular drug innovations in recent years and highlights how pharma continues to evolve toward more targeted and mechanism-based therapies.

Exciting to see innovation reshaping chronic disease management.”

Khokon Miah Akanda

Stay updated with Hemostasis Today.

aldosterone synthase inhibitor AstraZeneca baxdrostat Baxfendy Blood Cardiology cardiovascular risk FDA Health Hematology Hemostasis News Hemostasis Today High blood pressure Hypertension drug Hypertension Therapy Khokon Miah Akanda Medicine systolic blood pressure US FDA
NewsFeed